Chelsea Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).
Fast Track designation is designed to facilitate the review of products that address serious or potentially life-threatening conditions for which there is an unmet medical need.